Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CHRS 
Coherus BioSciences Inc (CHRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CHRS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.67
1 Year Target Price $5.67
| 3 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.72% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 147.61M USD | Price to earnings Ratio 2.4 | 1Y Target Price 5.67 |
Price to earnings Ratio 2.4 | 1Y Target Price 5.67 | ||
Volume (30-day avg) 7 | Beta 0.89 | 52 Weeks Range 0.66 - 2.43 | Updated Date 09/16/2025 |
52 Weeks Range 0.66 - 2.43 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 66.03% | Operating Margin (TTM) -443.59% |
Management Effectiveness
Return on Assets (TTM) -9.93% | Return on Equity (TTM) 33.11% |
Valuation
Trailing PE 2.4 | Forward PE 41.15 | Enterprise Value -46674816 | Price to Sales(TTM) 0.54 |
Enterprise Value -46674816 | Price to Sales(TTM) 0.54 | ||
Enterprise Value to Revenue 0.78 | Enterprise Value to EBITDA 3.54 | Shares Outstanding 116227000 | Shares Floating 111186498 |
Shares Outstanding 116227000 | Shares Floating 111186498 | ||
Percent Insiders 6.52 | Percent Institutions 47.53 |
Upturn AI SWOT
Coherus BioSciences Inc
Company Overview
History and Background
Coherus BioSciences Inc. was founded in 2010. It is a biosimilar company focused on developing and commercializing biosimilar versions of existing drugs. Over time, it has expanded its portfolio to include proprietary immuno-oncology assets.
Core Business Areas
- Biosimilars: Coherus develops and commercializes biosimilars for various therapeutic areas, including oncology and immunology. These are follow-on versions of innovator biologic drugs.
- Proprietary Immuno-Oncology: Coherus is developing its own proprietary immuno-oncology assets, aiming to provide innovative cancer treatments.
Leadership and Structure
The leadership team includes Denny Lanfear (CEO) and other key executives in research, development, and commercialization. The organizational structure is typical of a biotechnology company, with functional departments focused on research, clinical development, regulatory affairs, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Udenyca (pegfilgrastim-cbqv): Udenyca is a biosimilar of Neulasta used to reduce the risk of infection in patients receiving chemotherapy. Competitors include Amgen (Neulasta, Neulasta Onpro), Sandoz (Ziextenzo), and Mylan/Biocon (Fulphila). Udenyca has obtained a significant market share since launch.
- Cimzia Biosimilar (adalimumab-aqvh): Yusimry is a biosimilar to Humira (adalimumab) used for autoimmune disorders. Competitors include Amgen, Sandoz, Boehringer Ingelheim, and other Humira biosimilar manufacturers.
- Loqtorzi (toripalimab-tpzi): Loqtorzi is a novel PD-1 inhibitor being investigated for Nasopharyngeal Carcinoma. Competitors include Keytruda and Opdivo.
Market Dynamics
Industry Overview
The biosimilar market is growing rapidly, driven by increasing healthcare costs and the expiration of patents on blockbuster biologic drugs. The immuno-oncology market is also expanding due to advancements in cancer treatment.
Positioning
Coherus is positioned as a player in both the biosimilar and immuno-oncology markets. Its competitive advantage lies in its ability to develop and commercialize biosimilars at competitive prices and its investment in novel immuno-oncology assets.
Total Addressable Market (TAM)
The global biosimilars market is projected to reach hundreds of billions of dollars in the coming years. The immuno-oncology market is also a multi-billion dollar market. Coherus is positioned to capture a share of both markets through its product offerings.
Upturn SWOT Analysis
Strengths
- Established biosimilar development and commercialization capabilities
- Growing portfolio of biosimilar products
- Investment in proprietary immuno-oncology assets
- Experienced management team
Weaknesses
- Reliance on regulatory approvals for new products
- Competition from other biosimilar manufacturers
- Dependence on key patents and intellectual property
- Potential for pricing pressure in the biosimilar market
Opportunities
- Expanding biosimilar market in developed and emerging countries
- Potential for new biosimilar approvals
- Development of novel immuno-oncology therapies
- Strategic partnerships and collaborations
Threats
- Increased competition in the biosimilar market
- Changes in regulatory requirements
- Patent challenges and litigation
- Economic downturn and healthcare cost containment
Competitors and Market Share
Key Competitors
- AMGN
- SNY
- VTRS
- BMY
Competitive Landscape
Coherus faces competition from larger pharmaceutical companies and other biosimilar manufacturers. Its advantages include its focus on biosimilars, its experienced management team, and its investment in novel immuno-oncology assets. Its disadvantages include its smaller size and limited financial resources compared to its larger competitors.
Major Acquisitions
Surface Oncology
- Year: 2023
- Acquisition Price (USD millions): 65
- Strategic Rationale: Expanded immuno-oncology pipeline with clinical and pre-clinical stage assets.
Growth Trajectory and Initiatives
Historical Growth: Coherus has experienced growth in revenue as it has launched and commercialized new biosimilar products. However, growth has been affected by competition and pricing pressures.
Future Projections: Future growth is expected to be driven by continued expansion in the biosimilar market and the potential success of its immuno-oncology assets. Analyst estimates vary depending on the company's product pipeline and market conditions.
Recent Initiatives: Recent initiatives include the development and commercialization of new biosimilars, investment in immuno-oncology research, and strategic partnerships to expand its market reach.
Summary
Coherus BioSciences is a company with a growing portfolio of biosimilars and an emerging immuno-oncology pipeline. Its strengths lie in its development capabilities and product offerings. However, competition and pricing pressures pose challenges. The company should continue to innovate and capitalize on growth opportunities in the biosimilar and immuno-oncology markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Investor Relations
- Third-party Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and based on available data. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coherus BioSciences Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-11-06 | Chairman, President & CEO Mr. Dennis M. Lanfear | ||
Sector Healthcare | Industry Biotechnology | Full time employees 177 | Website https://www.coherus.com |
Full time employees 177 | Website https://www.coherus.com | ||
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.